BusinessPhoto: NDTV BusinessEmcure Pharma Shares May Rise 33% on Strong Growth Outlook
Motilal Oswal forecasts Emcure Pharma's revenue to grow at a CAGR of 15.2% from FY26 to FY28, driven by stable growth in domestic formulations and international business. The domestic segment is expected to grow at 12.4% CAGR, while the international business may grow at 17.4% CAGR, supporting a potential 33% rally in Emcure Pharma shares.
NDTV Business·


